Dr Reddys Labs net profit up 77 percent at Rs 1247 crore in Q3

Hyderabad: Dr Reddy's Laboratories has reported a 77 percent increase in its consolidated net profit at Rs 1,247 crore in the third quarter ended December 31, 2022.

The drug firm had reported a net profit of Rs 706 crore in the October-December period of the previous fiscal.

Read also: Dr Reddy's Labs acquires trademark rights of breast cancer drug from Pfizer

Revenue from operations rose to Rs 6,770 crore during the period under review as against Rs 5,320 crore in the year-ago period, Dr Reddy's Laboratories said in a regulatory filing.

Read also: Dr Reddy's labs completes clinical studies of Rituximab biosimilar for filing in US, Europe

Established in 1984, Dr. Reddy’s Laboratories Ltd. is a global pharmaceutical company headquartered in Hyderabad, India. The company offers a portfolio of products and services including APIs, generics, branded generics, biosimilars and OTC. Its major therapeutic areas of focus are gastrointestinal, cardiovascular, diabetology, oncology, pain management, and dermatology. Dr Reddy's major markets include – USA, India, Russia & CIS countries, China, Brazil, and Europe.

Read also: Dr Reddy's Labs, Theranica collaborate for commercialisation of wearable migraine treatment Nerivio in India